Finance

Lists
1099:HKG
Sinopharm Group Co Ltd
15,72 HKD
+0,45%
(+0,070) 1D
16-окт., 16:08:14 GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 1099...
Open
15,79 HKD
High
15,99 HKD
Low
15,67 HKD
Mkt. cap
49,06 млд
Avg. vol.
4,85 млн
Volume
5,89 млн
Dividend
5,03%
Quarterly dividend
0,20 HKD
Ex-dividend date
2026-ж., 23-июн.
P/E ratio
5,90
52-wk high
22,34 HKD
52-wk low
14,55 HKD
EPS
2,67 HKD
Shares outstanding
1,19 млд
No. of employees
90 миң
Open
15,79 HKD
High
15,99 HKD
Low
15,67 HKD
Mkt. cap
49,06 млд
Avg. vol.
4,85 млн
Volume
5,89 млн
Dividend
5,03%
Quarterly dividend
0,20 HKD
Ex-dividend date
2026-ж., 23-июн.
P/E ratio
5,90
52-wk high
22,34 HKD
52-wk low
14,55 HKD
EPS
2,67 HKD
Shares outstanding
1,19 млд
No. of employees
90 миң
News stories
From web sources and news partners
Profile
Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical. Its H shares were listed on the Hong Kong Stock Exchange in 2009, with its IPO price of HK$16 per share. Sinopharm Group's subsidiary Sinopharm CNMC and Sinopharm Accord served as the A share counterpart of the company. However, the A share of Sinopharm Group itself was unlisted. Sinopharm Group was ranked 829th in 2016 Forbes Global 2000 list. Wikipedia
About Sinopharm Group Co Ltd
CEO-
Employees90,4 миң
Founded2003
Headquarters-
SectorHealth care provider
Last report
2026-ж., 24-авг.
Fiscal period
Q2 2026
- / -
Revenue / Est. (CNY)
142,03 млд / -
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
145,44 млд
143,69 млд
140,77 млд
142,03 млд
Cost of goods sold
134,52 млд
133,28 млд
131,40 млд
132,33 млд
Cost of revenue
134,52 млд
133,28 млд
131,40 млд
132,33 млд
Research and development expenses
172,61 млн
-172,61 млн
46,59 млн
-46,59 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,17 млд
7,34 млд
5,10 млд
5,70 млд
Operating expense
6,80 млд
5,00 млд
6,29 млд
5,45 млд
Total operating expenses
141,32 млд
138,29 млд
137,69 млд
137,78 млд
Operating income
4,12 млд
5,40 млд
3,07 млд
4,26 млд
Other non operating income
120,78 млн
-427,44 млн
39,60 млн
-100,78 млн
EBT including unusual items
3,67 млд
3,92 млд
2,90 млд
4,05 млд
EBT excluding unusual items
3,51 млд
5,36 млд
2,90 млд
4,25 млд
Income tax expense
905,42 млн
1,19 млд
712,28 млн
1,05 млд
Effective tax rate
24,66%
30,30%
24,57%
26,02%
Other operating expenses
917,07 млн
-1,10 млд
204,49 млн
-392,73 млн
Net income
1,84 млд
1,85 млд
1,41 млд
1,99 млд
Net profit margin
1,27%
1,29%
1,00%
1,40%
Earnings per share
-
-
-
-
Interest and investment income
364,24 млн
-
171,27 млн
-
Interest expense
-412,56 млн
-846,59 млн
-383,82 млн
-505,78 млн
Net interest expenses
-48,32 млн
-846,59 млн
-212,55 млн
-505,78 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
4,66 млд
5,91 млд
3,58 млд
4,78 млд
Gain or loss from assets sale
11,79 млн
-20,53 млн
-
-14,32 млн
AI content may include mistakes. Learn more
Google колдонмолору